Dr. Schiff prepares and prosecutes patent applications, determines freedom to operate, and does portfolio valuation and due diligence in the context of corporate transactions and licensing.  He helps clients optimize their investment in intellectual property in view of product release dates, economic constraints, technology life cycle, and potential financing opportunities.

As a cost-effective approach to patent prosecution, Dr. Schiff regularly visits the Patent Office to negotiate commercially valuable coverage with patent examiners.  He has obtained patents in a variety of technology areas including biotherapeutics, medical devices, gene sequencing, nautical mechanics, new chemical entities, microfluidics, clean energy, and power management systems.  He also does pro bono work in the field of immigration law.

Concurrently with his position at Kilpatrick, Dr. Schiff is Senior Director of Patent Prosecution for Unity Biotechnology, located in Brisbane, California. Unity was a venture-capital financed start-up when he joined the company in 2016. Unity had its initial public offering in May of 2018, and is now publicly traded.

Before entering the practice of law, Dr. Schiff did laboratory research on the cell biology of vesicularized molecular transport.  In the course of the project, he programmed computer models for Monte Carlo simulation of ligand-receptor binding kinetics.  He was awarded the Hardi Cinader Graduate Student Prize at the University of Toronto.  He has also served as Director of Intellectual Property for Geron Corporation in Menlo Park, and Vice President of Intellectual Property for Meyer Pharmaceuticals.

When not engaged in intellectual property law, Dr. Schiff is an occasional endurance athlete, participating in triathlons and team adventure races in the U.S. and abroad.